SGLT2 inhibitors can reduce inflammation,8, 9 via different mechanisms including attenuation of the nucleotide binding domain-like pyrin domain 3 (NLRP3) inflammasome, which correlates with disease severity in COVID-19.10, 11 A meta-analysis of 26 trials in patients with type 2 diabetes showed a reduced risk of pneumonia and septic shock among those receiving SGLT2 inhibitors.12 Here, SLC5A2 is linked to type 2 diabetes mellitus.